09:57 AM EST - IMV Inc. : Announced positive preliminary data from the VITALIZE Phase 2B trial evaluating its lead DPX product, maveropepimut-S, in combination with pembrolizumab in patients with relapsed, refractory Diffuse Large B Cell Lymphoma. IMV Inc.
shares T.IMV are trading down $0.42 at $2.15.
